Oslo, 12 February 2026 - In the fourth quarter of 2025, Navamedic ASA achieved
its highest quarterly revenue ever at NOK 157.1 million, a 19.8 per cent growth
compared to same period last year. This reflects a full quarter with revenues
from the Addiction portfolio that was acquired on 15 July 2025. For the full
year, Navamedic reported revenues of NOK 565.4 million, marking a 6.4 per cent
increase over 2024. Adjusted EBITDA for the quarter amounted to NOK 13.4
million, while the full-year adjusted EBITDA came in at NOK 47.6 million.

"We have completed a good fourth quarter with strong growth both as a result of
the acquisition that we completed in July and an increase in demand for our
products within antibiotics. We continue working on improving our gross margins,
and I am pleased to see that we have achieved above 40 per cent in the quarter,"
says Kathrine Gamborg Andreassen, CEO of Navamedic.

The growth in the fourth quarter was driven by the addition of the acquired
Addiction portfolio as well as a significant increase in sale of antibiotics to
Nordic hospitals after recent tender wins during 2025. This translated into a
growth for Prescription Drugs of 24.1 per cent in the quarter, and a growth for
Hospital of 40.3 per cent in the quarter compared to the same quarter last year.
Consumer Health saw a 6.6 per cent reduction in revenues in the fourth quarter
compared to same quarter last year mainly due to periodization of campaign
activities.

The growth for full-year 2025 of 6.4 per cent was largely due to strong growth
within antibiotics and the impact from the acquired Addiction portfolio. The
resulting growth in Hospital was 22.9 per cent in 2025, while Prescription Drugs
and Consumer Health grew at 10.5 per cent and 2.3 per cent respectively.

Gross margin came in at 40.3 per cent in the quarter, a significant improvement
from the result in the same period last year of 33.7 per cent. The full-year
gross margin in 2025 was on par with last year at 39.0 per cent.

"We have managed to grow the company in 2025 without any large out-licensing
milestones, and in a market for obesity products that has continued to be very
competitive. With the full-year effect of the addiction portfolio and some
growth in other product areas, I believe we should be able to continue a similar
growth path in 2026. We will also work hard to stabilize our gross margins above
40 per cent," says Kathrine Gamborg Andreassen.

"The launch in December 2025 of Flexilev in OraFID for advanced Parkinson's care
reflects our commitment to be a proud contributor to public health and was an
important milestone in our growth plan, but the volume for this product will
still be modest in 2026," says Kathrine Gamborg Andreassen.

Presentation and webcast

CEO Kathrine Gamborg Andreassen and CFO Nils Ole Krekling will present the
results today at 08:30 CET at Haakon VIIs gate 2, Oslo, Norway. The presentation
will be streamed live and available on demand via the following link:
https://navamedic.com/investors/

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, mobile: +47 951 78 680
Nils Ole Krekling, CFO, mobile: +47 924 24 016

About Navamedic
Navamedic ASA is a full-service provider of high-quality healthcare products to
hospitals and pharmacies. Navamedic meets the specific medical needs of patients
and consumers by leveraging its highly scalable market access platform, leading
category competence and local knowledge. Navamedic is present in all the Nordic
countries, the Baltics and Benelux, with sales representation in Greece.
Navamedic is headquartered in Oslo, Norway, and listed on the Oslo Stock
Exchange (ticker: NAVA). For more information, please visit www.navamedic.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.